Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 448

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 448
---
 SPA, relating to a committed equity facility. Pursuant to the Facility SPA, the Company has the right from time to time at its option to sell to Alpha up to $25.0million of the NLS Common Shares, subject to certain conditions and limitations set forth in the Facility SPA. Upon the initial satisfaction of the conditions to Alpha’s obligation to purchase NLS Common Shares set forth in the Facility SPA, or the Commencement, including that a registration statement registering the resale by Alpha of the NLS Common Shares under the Securities Act that may be sold to it by the Company under the Facility SPA, or the Initial Resale Registration Statement, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC, the Company will have the right, but not the obligation, from time to time at its sole discretion until the first day of the month next following the 36 -monthperiod from and after Commencement, to direct Alpha to purchase up to a specified maximum amount of NLS Common Shares as set forth in the Facility SPA by delivering written notice to Alpha prior to the commencement of trading on any trading day. The purchase price of the NLS Common Shares that the Company elects to sell to Alpha pursuant to the Facility SPA will be 95% of the volume weighted average price of the NLS Common Shares during the applicable purchase date on which the Company has timely delivered written notice to Alpha directing it to purchase NLS Common Shares under the Facility SPA. In connection with the execution of the Facility SPA, the Company agreed to issue a pre -fundedwarrant, or the Pre -FundedWarrant, to purchase $250,000 in NLS Common Shares to Alpha as consideration for its irrevocable commitment to purchase the NLS Common Shares upon the terms and subject to the satisfaction of the conditions set forth in the Facility SPA. Operating Results Operating Expenses Our current operating expenses consist of two components — research and development expenses and general and administrative expenses. Research and Development Expenses, net Our research and development expenses are expensed as incurred and consist primarily of costs of third -partyclinical consultants who conduct clinical and pre -clinicaltrials on our behalf and expenses related to lab supplies, materials and facility costs. Clinical trial costs are a major component of research and development expenses. We accrue and expense clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical sites. We determine the actual costs through monitoring patient enrollment and discussions with